TACE-HAIC combined with targeted therapy and immunotherapy versus TACE alone for hepatocellular carcinoma with portal vein tumor thrombus: a propensity score matching study.
Yichuan YuanWei HeZhiwen YangJiliang QiuZhenkun HuangYunxing ShiZhu LinYun ZhengMinshan ChenWan Yee LauBinkui LiYunfei YuanPublished in: International journal of surgery (London, England) (2023)
Compared with TACE alone, combination therapy was safer and resulted in survival benefits. This is a promising treatment option for HCC patients with PVTT.
Keyphrases